sar405838 and Brain-Neoplasms

sar405838 has been researched along with Brain-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for sar405838 and Brain-Neoplasms

Article	Year
Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy. Drug metabolism and disposition: the biological fate of chemicals, 2019, Volume: 47, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Blood-Air Barrier; Brain; Brain Neoplasms; Dogs; Humans; Indoles; Madin Darby Canine Kidney Cells; Mice, Transgenic; Models, Biological; Neoplasm Proteins; Proto-Oncogene Proteins c-mdm2; Spiro Compounds; Tissue Distribution; Tumor Suppressor Protein p53	2019
Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Molecular cancer therapeutics, 2018, Volume: 17, Issue:9 Controversy exists surrounding whether heterogeneous disruption of the blood-brain barrier (BBB), as seen in glioblastoma (GBM), leads to adequate drug delivery sufficient for efficacy in GBM. This question is especially important when using potent, targeted agents that have a poor penetration across an intact BBB. Efficacy of the murine double minute-2 (MDM2) inhibitor SAR405838 was tested in patient-derived xenograft (PDX) models of GBM. Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Female; Glioblastoma; Humans; Indoles; Male; Mice; Proto-Oncogene Proteins c-mdm2; Spiro Compounds; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2018

Article

Year

Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy.

Drug metabolism and disposition: the biological fate of chemicals, 2019, Volume: 47, Issue:12

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Blood-Air Barrier; Brain; Brain Neoplasms; Dogs; Humans; Indoles; Madin Darby Canine Kidney Cells; Mice, Transgenic; Models, Biological; Neoplasm Proteins; Proto-Oncogene Proteins c-mdm2; Spiro Compounds; Tissue Distribution; Tumor Suppressor Protein p53

2019

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.

Molecular cancer therapeutics, 2018, Volume: 17, Issue:9

Controversy exists surrounding whether heterogeneous disruption of the blood-brain barrier (BBB), as seen in glioblastoma (GBM), leads to adequate drug delivery sufficient for efficacy in GBM. This question is especially important when using potent, targeted agents that have a poor penetration across an intact BBB. Efficacy of the murine double minute-2 (MDM2) inhibitor SAR405838 was tested in patient-derived xenograft (PDX) models of GBM.

Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Female; Glioblastoma; Humans; Indoles; Male; Mice; Proto-Oncogene Proteins c-mdm2; Spiro Compounds; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2018